<SEC-DOCUMENT>0001193125-12-293405.txt : 20120703
<SEC-HEADER>0001193125-12-293405.hdr.sgml : 20120703
<ACCEPTANCE-DATETIME>20120703132817
ACCESSION NUMBER:		0001193125-12-293405
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120629
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120703
DATE AS OF CHANGE:		20120703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		12943554

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d376366d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): June&nbsp;29, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. PHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code:&nbsp;(650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General
Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01&nbsp;Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;29, 2012, A.P. Pharma, Inc. (the &#147;Company&#148;) announced additional data from the Company&#146;s Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting
(CINV). APF530 is the Company&#146;s lead product candidate being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The Company presented the study results at a poster presentation during the
Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) International Symposium in New York. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01&nbsp;Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Document Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on June 29, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. PHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: July&nbsp;3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d376366dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g376366g34u43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#150; Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology
International Symposium &#150; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; June&nbsp;29, 2012 &#150; <U>A.P. Pharma, Inc.</U> (OTCBB:
APPA.OB), a specialty pharmaceutical company, today announced additional data from the Company&#146;s Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV). The findings from the analysis of this subset of
data indicate that APF530 offered comparable nausea control and patient satisfaction to palonosetron (Aloxi<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>)
over a 5-day period. The Company presented the study results today at a poster presentation during the <U>Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) International Symposium</U>
in New York. As previously reported, the Phase 3 study showed APF530 was comparable to palonosetron in preventing both acute- and delayed-onset CINV in patients receiving either moderately emetogenic chemotherapy (MEC) or highly emetogenic
chemotherapy (HEC). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Delayed-onset nausea and vomiting remains a major issue associated with many cancer treatment options, which can
affect a patient&#146;s quality of life as well as his or her ability to sustain the recommended potentially lifesaving chemotherapy regimen,&#148; said Rebecca A. Clark-Snow, RN, BSN, OCN, clinical nurse coordinator and chair of the MASCC
Antiemetic Study Group. &#147;In particular, patients who have experienced nausea and vomiting during previous chemotherapy treatments are more susceptible to experiencing a recurrence during subsequent therapy. These data indicate that APF530 has
the potential to be a promising therapy option for physicians and patients.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Study Results </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The study found patient satisfaction between patients administered APF530 and palonosetron to prevent CINV following MEC or HEC were comparable, with no
statistically significant differences. The severity of nausea experienced by patients in the study was also comparable with no statistically significant differences. These findings held for subgroups of patients regardless of whether, or not, they
had previously received chemotherapy treatment. The study also showed that for each day of a 5-day period there were no statistically significant differences between APF530 and palonosetron in patient satisfaction and severity of nausea. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;These data indicate that APF530 has the potential to provide both comparable antiemetic effects and patient satisfaction results to
palonosetron,&#148; said John Whelan, A.P. Pharma&#146;s president and chief executive officer. &#147;Our continued analysis of the Phase 3 study further demonstrates the potential role APF530 could play as a new therapeutic agent in cancer
care.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more
-</I> </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Announces Positive APF530 Patient-Satisfaction</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 2
</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting</I><B><I> </I></B><I></I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Study Design </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s pivotal Phase 3 clinical trial was a multicenter, randomized, observer-blind, actively-controlled, double-dummy, parallel group study that compared the efficacy of APF530 with
palonosetron. The trial stratified patients into two groups, one receiving moderately and the other receiving highly emetogenic chemotherapeutic agents in accordance with the Hesketh algorithm, which assigns emetogenic levels based on the
chemotherapy agent, drug dosage and combinations employed. In each group, the patients were randomized to receive in the first chemotherapy treatment cycle either APF530 high dose (10 mg granisetron), APF530 low dose (5 mg granisetron) or the
currently approved dose of palonosetron. Patients used a daily diary to record severity of nausea, vomiting/retching episodes, use of rescue medication, and satisfaction with nausea/vomiting control over a 5-day period following chemotherapy.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About CINV </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prevention and
control of nausea and vomiting, or emesis, are very important in the treatment of cancer patients. The majority of patients receiving chemotherapy will experience some degree of emesis if not prevented with an antiemetic, typically administered just
prior to chemotherapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chemotherapy treatments can be classified as moderately emetogenic, meaning that 30% to 90% of patients experience
CINV, or highly emetogenic, meaning that more than 90% of patients experience CINV, if they do not receive an antiemetic. Acute-onset CINV occurs within the first 24 hours following chemotherapy treatment. Delayed-onset CINV occurs more than 24
hours after treatment and may persist for several days. Prevention of CINV is important because the distress caused by CINV can severely disrupt patient quality of life and can lead some patients to delay or discontinue chemotherapy. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s lead
product, APF530, is in development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company&#146;s proprietary
Biochronomer&#153; drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of
acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products
using its proprietary Biochronomer&#153; polymer-based drug delivery technology. The Company&#146;s primary focus is on its lead product, APF530, for the prevention of CINV. A.P. Pharma received a Complete Response Letter on the APF530 NDA and is
targeting the resubmission of the NDA in mid-2012. The Company has additional research and development programs that utilize its bioerodible, injectable and implantable delivery systems. For further information, please visit the Company&#146;s web
site at <U>www.appharma.com</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more
-</I> </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Announces Positive APF530 Patient-Satisfaction</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 3
</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting</I><B><I> </I></B><I></I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This news release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties,
including uncertainties associated with capital resources and liquidity, timely development and regulatory approval of product candidates, satisfactory completion of clinical studies, progress in research and development programs, launch and
acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date.
We do not intend to update them except as required by law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 646-597-6979 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email:
<U>mrice@lifesciadvisors.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President and Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g376366g34u43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g376366g34u43.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,@"5`P$1``(1`0,1`?_$`*T```$#!0$!`0``````
M```````!"`D"`P4'"@8$"P$``00#`0$```````````````(#!P@!!08)!!``
M``8!`P,"`P4'!0$!`````0(#!`4&!P`1""$2"3$3010546$B,A9QD:%"(Q<*
M@;'!T1@S&A$``0(%`P(#!08$!`8#`````0(#`!$$!08A$@<Q05$B$V%QD3((
M@<%"%!46H;'1(_!B@C/A4G+"%Q@D)37_V@`,`P$``A$#$0`_`._C1!!H@A!'
M8-_^Q_@'WZ.G6"(Y.57E+X><257T%?+^6VY$9I&$<98T32MUM;J["":4T+5P
ME"5?O,'7Z@[;J`&X@0=2CA/#.?Y\L/6FB6BUGJ^]-#0^PB9]A"2#XQ#V>\W\
M=X"V6KK6-OW8#1A@[W)_]0,A\9^R(.LH_P"1]DI^Z<M\+\<*9`18'4(RE<FV
MN:LTH<I>A%58>L)UZ/1-OZD!XN`;?F'H.K)V7Z0:%82+_=7U])BG;"`/$!2M
MTP.QTT[15V]?6E<W=S5@LK"4S(2I]9693TF!MUE+=[>AC44-_D2\P6<@@M+8
MJP!,QY3E]Z-;15YA7#HNVPD2D?UA)@V.(]0$450W#T'70/\`T?X(&EFFN=U;
M?'3U"E8^&T1S5/\`61G5/4)556ZVJ9GYDH"DGX[C+X1.?X]_+7AGG/(*X]=P
M;O$N<VD>O*#0)B42EXJT1S,@'D7]$LB;9C]6&.*/N.&2Z"#Q%$>\"J)@8X5A
MY/X1R'C<"XJ<_/6%Q0'K!.T-GI)2=9>Q4]3X3BU?$7/V-\IK-O4V*'(T)F&E
MJF'!W*%:3/B):>)B6I$H%*(!OMW;_=Z!Z?9O_OJ%TD%,P=R>Q\8GE"$-E26P
M0G=T[#W>R+NE0Y!H@@T00:((-$$&B"#1!!H@@T00:((-$$6SF]0Z[]/^!^`[
MZ0XE"D;5S"=.GOT_C!K^&4_;'B[Y?Z?C.I6*\W^Q150IM5C5Y:P62=?(L(J+
M8(%[E%G+I90NPG$0*0A=U%#F`I`$P@`_91VZNNU<U;+2PY4W-U00A")S*E:#
MIV\3V'6/ANMRMEAMJ[O=*ANGM[*2M:U'221,RGU,AH!J>PCCT\AWF\R7G-Y-
M8KXK2<WB3$'<[C9&^(*'B\H9$;)]Z:BC54I@=T6LO41W330[9-=,VZJJ("*0
M7^XI^F>@Q]EC),Y#55=U`*2Q,*0P>OG09A:@>Y!`[3ZQYU\P_4_=\F<>Q_!/
M5I+*%%)>U"WQ/JE8D4`]0`?>8@*.HHJJNNJH=5=RL=PY65.919RX4.*BCAPJ
M<3*+KJ*")C'.(F,8=Q'?5KFD(8;]%@!#/_*D;4_`2$4V===?<]9Y2ENGNHDG
MXG6$[@`>P2@4_P"8H&$`.H&W42^O<'3H/_0Z?+SS29O)2&Y:>:6G:%(2G?ZC
M*U%1$OEGKWA2'(J!C)G3,!1V-V*E-VB&^X")1'8WW>O^FFVIU14M#B`A/@K<
M?YP.H_+@!Y"U+5_S`C^,;CX\7^QXKSYAK)%4>KLI^H9,I,JQ41.8AER!8&+-
M\Q/[>QE&\I%.UVJI!'8R:HAZ"(:Y7-K31Y'A=SH*PA31HW2"0.J0>Q\#T/VQ
MU^#7.KL&8VRNH@IM]-6V-">BB#U!'7O'Z8Z:@[;]IQ*(_P`I1$"?<(%ZB(#\
M->-X*4)VH`V@J&@/91'81[;H*W$I)3U"2=0.J09:F+H"("`B)AZ&W'TVV$/P
M[`.PCUUA3BB1M3)(Z]?O`A8]-1+O0C24Y_RB+'ECSUO.#^97%#B3C6C56XRV
M?G;)Q;9>Q24T@O3Z^\M'TE-[',X?M*Y6"*BY-P/S!O;W;D#\HF'4N8EQM09+
M@5ZS2Z5#]/2VP`-AM((=4=9*).@W;4S&LS*40GGO*USQGD2R8%9:9BIK;J?[
MN]1!:3/YDR_%M"C(Z:1*9W#WE`0,`;#U,(AM\=Q`![MQ`/00U$32I`"13,;N
M_7N-?#K*)J.XK\@'J)4>I'3W#L>FL!E"@!@.80`!V'<=O7KT-T`=OVZQZB'B
M4LDDCKY5$?$#[X2IS:9J`0>TU`$^Z>D*!_PB(^X`;;AW!L.WPV#[!TXI*UID
MD@*]Q^^,I"T@E4U`^T?=%LZY2[&/NF4-@[CB!2E$1[0[CF,!>ING7;KT]=-2
M/61D?8K0^)]D(*B9*`T2>NY,C_EZ]8J^83`H&'OZ!W#L4>@%#<3#U$`*`?'?
M;3@*B`-P)\0DR/N_X3AV7X3).W4@J$Q[]8^=%\S71]]!RFLV`%!%RDL15``3
M'^H;WB'%,"ICZ]>FD!:$J+*2H.DDR*5S_B(9]5M3)<W)73SU6%ID#WUGH(K;
M/FKM/WFCE)TB(F*55LLFX2,8H]IRE52.9/N)MU#?II;J5@`J*F_>G^NL*:<;
M=3O94A;4I`I5NG[Y18<RL;''3"1D63(SD1!N5X\;M17`-MBH>^LG[H]?Y0$>
MNLH;+R2EL+4V.OE5_.4(6_3L+!J%(:<(D-RQK+V$QD/<)V]VYMNX/YB^G8)M
M]^[\O;U_9UUC^W_MS]DM9SZR\9P[+3?,[.LYB4O'PE]\6W[ILR:.G;M=%JV:
M(*.73I=0B*#9L@055W#A=02)HH((E$QS&$`*4!$=.(;6\M+3:2IU1`2`)DJ)
MT``U))E"*EQIFG6]4+#=.A)4I1,@E*1-1)[``&.*CR!^1QGS2Y0TO$\37;SD
M7AS0,AL6BV,L;2+^*MV?Y&,='1D;(DLQ:O'ZQ#'3,$$T!(0*V*9<1366!1+T
M%XOX<=P'"*C*:ZIH[?G%6T-E4_+TJ$2GM7,Z*5^+^@CS=Y7YJ;Y$SNEQ2WTU
M76X+1OR53L$AVND9$@@'R]0GP!\8D^XSX'@,VLLJU+/OBEQ%Q=XN,,<V&7H=
MPG(YDWS*BNU.`LCSDFNY&T)S)H0RSXSL"-S-UT0#O4WW&%\PRNIQFIM]?CN<
M5EWS5ZI"*A+6X4P3/789;5`GL)Z'M$X8EBU#D+-PH,FPBCLV'M4BELK<E^8F
M$D@K.Z>[J9R$B.^L<>;GY0';PC$ZBK)-X\(R65`ON+,BN#E9*J=O3W#MBE$1
M#H(B(_'7H=2+6NG*EDE<H\S:L)0^4HD$3CH!X^U7CKQJ\1+KDYFOCAC[.U\R
MUFUQ%T".NK9)HX<-FDL2)@T5+`B@><;5=D:GOGCQJT.4'B9C)F$"J&$*@9=6
M9/G7._[!L=UK+?;*.E2IXM*\LU)F3MU222X@3/0CV1<[#:/#\!X$1GF3VBBK
M[U65933I>1,D`F1GH9>4G364H]+G8<%\RO$G;N6Y>.>*./F7<,9-8U",>XJA
M&T##3S9*PUJ%=QC446C-V_BY6*M!1%N[%PHV>M>XBFV^_P`>.#)^-.?:?"#=
M*NZ6JLI"ZH.+*@%$*U(Z`@IGI+0C2-CE*<4Y%^G^HSQ-GHK7>J6I#2?21MF!
MMT!ZF>[X@Q%7XZ<!27)7F1@S'C9HHO"LKC&7VZN"(G4;Q]+H3MM9)M9T</Z9
M2/CM$&28&'8RSHH>HZL#S1E%/B7'%QN;KI16O,*:92.I4ORF0]YF?9,Q7CA'
M#ZW,N1;9:V4E5&BI2XZKKM2WYR3X&0*?X1/?FU?.?,GS%W?CYBOD;E7"6.,.
MXI9-[G(8[G)!$$`:0;1Q9D6$+\ZG!!8Y>5O23$CYPBH=J"'<4!,4@!5#%_V_
MQYP13YA=[517"\W*I4IM#Z`HI"E;!J1/R["N7B9Q<3)U9-R;SW5X39KM6VVQ
M6^E0EY3"RD%0&Y1('4DKV?Z9=!&"XQ1>7.%'F"B>(4%GG*&9\1Y#H#J>GX[(
MT^^G7S4TC3):UL)*02<.731K/04G"E*#IN1#WVCOM4+N;?3F5*Q[.>`W,S%L
MH[=?*"J*=S20DNR.TI"M)A0.H\4^R/BP]O(>-?J$''R;E5W*Q5E,EQ0=45!,
MP2DD:R*2#K[?LCSU\Q?=.=7FNS/#47+-EQ!%<=\<-*X\R#2FS1U;(2.AX1C7
MYN(J+MV)FL-.34_>)%$KT0,JU(FH9,/<`!#[;=>+;QA]/-MJ;C0,7!=U?4X&
M7!_;4%;EI*Q^((V),NYETC7W&QW'E?ZE;A3VZO>H$V>G"?S#1DXF12A24&4@
M5!:A/PW1Z[QKUJ\8E\L_*C`-'S%E/)6%L9TB<;6H^1[4_L;J0L15Z8FP=/`6
M4.P&;B[#(O6Q'*22*BB!#E-OZ:^7EIZU7?A.QY5=:&EI<FKGCZ1IT!(#8*NL
MO%`$@9R)C;\,4%XLO/-\QNCN%758W0LD.>NLK)49;>IEHLGPZ1G_`""V+B#9
M.15Z3Y*^0'.-@@XR(8LJ9Q6XUHRKMYCN99LE$YYS9GE*9244_>&6("P)R(I/
M$C&.5=0$R$+K6<84F<TN*TZL4QFW,UQ>WJK[B4@OH)VA+:5D$C4Z"?0$#4Q]
MG+%5@-PRY\9;E%P>2EM26J"WA1#"TIGN<6@%`,Q^*74[B-(S_A>S;>:[PCY>
M9)O=UMMKQMB*T6^2QP\NDJ\EI&.B*Y0!L<K'MWS]=RHDBLLHT.9`BID47*J@
M$`O<.F^?[!9JCDBS6*@;8IKG4-4Z*LLI"6_56X$E0`ZRF3/N)0?3GDMZ5QED
M%[N#S[]MIG'S2*>42O8AM1"9GM,)'OG#7?%5PYY#<OZC6\^Y7Y&7B%P/&Y]+
MD=AC)O*SLQ(93M].EF"\F:U/GDPBC'TYHZ:BR;-@!<`,"QR)D[MQ[#FS,L6P
M:M>Q"TVFD=R5VVMM.590D;6RF4T:'SGJ=!VU[1RG`N#9?GU(WE]ZO#K>,LW)
MQQ%*%J/J.)(/FU'EU\3WT[QF>/&$K%Y*.=//JYV'/&8\=X&J]T4J<E%XVN$A
M"*6^&0EWT-!5A.2677:0L`W:4GY]T"#83.3*%`=BB(C\F79!;>+..L:M=#:Z
M2HR>HI6W-[[84MM:I$J`ZDE2MO42!AO#+#4\O<EY/>*BZUU'B],^XDH8<4E*
MT`D`$]-NT;OC*-8^,[B>_P"3JG+VGR/)3/=.X=XQR0Y;DJU0N7T=YD-9HK9Q
MB)&<G#(N`8LHNJQJ+AZ@T232?K+)BH78A=='S)FENQ%./N4EGH%\B5U.AU;B
MV@IML.(1-*1IKZD^^GMC2<,8-4Y@SD5%4WFX-\<T%2XE*&W2%N*1-0*O84:]
MY](>+_C[*.X7&'+VX2EODPPS%91CV=0<V^94^F0[*OPLN^G+"NYD'`1T8+B!
MD(X[Y0GMI'.CW&VVU'WU.AMZ[6&@IZ1+>0/425NAI$E.J<2A*1)(U\Z%;1_6
M)(^E!]VGM5_NC]6M6.LU6QI3JYAM*"I2E3.@)0I)/N$1_P#+R2X"6:$Y'7-?
MD3RUYEY]6?S\A1,IPC"PLL.8M<OGY$ZI6Y*901CJ<I`QRBB3=1P@0471.PK9
M-,1`PR;QP.5&*VTV)-JL-DQ[:D.L.)1^:J0?]QS:9J*E@3'@029B<1GR94<7
M+I+K>Q=[]>LB4M99>;*Q2TZC_MH*I`$(]A[C2)+_`-0Y7_\`SS#9_P!27#]=
M_P!CPDOU']8E/U5^D_[H"4%_K'S/U7Y;]"?@[O=[_DOP[]NHA_3[3_[0?I/I
M,_I_ZML].0V[O2G*73YM8E[\SDW_`*K?GO4?_5_R.[U/4._T_5^;=U^324;\
M\Y_)M_@CAT[H59E7$9=N0TX.-V;ADH*+QI3&[,)/(+Q%8@@HC\S%>U'"8NP@
M$@.PAMK1_3AAC67YZ:ZK1.UVIHO+GT+I(#/VA1WCMY=8Z3ZH,W?Q3CE5LHG-
MMVNK@93(`GTA(N^X$>6?^8Q"SX5;'@>HP?+23GLKXLPWR>DZ&VK>!;QE9]%Q
M4966<C"3Q7D["/)@R;4[IO9S,Q?D0,+L6R1-BF3$P#83ZDZ3)';S8V6**JN&
M()<0Y5,,[O[Q"DS2K9K,HW!).@)[16KZ8ZO%J2QWRHJJVEM^9K96W25#\CZ!
M4A6U22KY0E>TJE(RG#B,=Y0Q/QBX><^I:T\_Z5RIY492ICVI'^FW">E#(OEX
MM_$(1F/W=M<E?W(OO6Y9VZ>1Z";1,R0)D#^F.W"7#'KWF>>8RU18JNR8A2.C
M<=B0HB85N=*=9^4`3).I\8[ZWWZSX=Q[E#U5E5)>LSJFB$#U5J0"=-J0HR/4
M_*`!*4_&)>]8&X@U#@'C;,4+FTUHY<V^9BVDUAZ&ME?>L:E!.I2<.LXF*VA&
MGG&;AC7(ML"AE'7:#MT`;?`+"6'+,\K>5JK&ZBVJ8P.F8=4*@I,G"@"1WGL3
M.4NH$5UO.%<?4G$M-D[-Q2_G54^A)IPK5L*)F"D=]!J1WTUB;[ESQMPY9^&G
M`KAE?.5.-^+MZHV,H3*)&&4F2Y*K;@=UP(NQF/+F?0[5E-P\]-.E$D%%@,Y]
MQ4`+^'O+6/`\TR2BY%R'.[59W[S3OU"Z<K:ZH2'/(`!V(;1J!/3P49V?Y!PC
M'KQQWC''E=>J:SW*GHT524OSV.!205^:4]R9KD)^/80U7)&6^%4I7>)GBRQK
MF=JXXQ0-X&X\H^1:+HE:BKI86[66FB,*Q)O&CLCIY,6Q<ABJHIN&Q51:-T16
M%,Q@[FUV+DJVU5ZYPO%M`RDM*_3Z->I99)V^JX`1\HF=AZZG2<HXB[7[CJY,
M6+@BS7/=BS3Z5U]8D>5]T3/IMS!,B3+</9+I,SR<%?'-@_@W-9<N^.5Y252R
M(,&C`3-G>EE)RO8ZB8AB^/%+R1F$8`GF9\7+]SVH)[)E;)CN*0CJMO(O*F4<
MG4]#07PI0[3!6Y+:4A*W5K/8>`DD:D:F+4<7\/8SQ747"[68E357(MJ6I14V
MR$S(UTF5:SE.6D0&\'.1O(^H<E>:/,S$W$JY<HJIES)EDI,@\I,D5O/U*05L
MCJVU](6B3.6>KPC^(.R(Z43;"1+VT@[P$=ALKR%AN*UF(8Y@N17QFR7*FH45
M`]5.YM3:P4*'4>::3+6?>457XMRG-*/-\FSS&;([>K?65CK!#:I+0L*+B>QT
MDH3\1I,2$2I^.GB+R(>\B,R^1/F?7T:MF/);)[#XXQ:55)W*4*J+$;-E!>)(
M.'"$8Z-7HQK&,FACF<D0!95?L47]LD*\K9QBS6*4/%N"NA=AHW=[]1KM?<!$
MBDGS2U65?A,Q+I$Z<1X)EKF47#E?D-@MY+5-;*>F&T+:0`N:2!I.6T)TGUGU
MCX_$-QXSECO(W.#D/R#QC:L>73,N4/FZW&VAHV2F92LFF+/;GRS5-!X[`6JK
MN<;MB=QBB*C?T``#6>9\EQZ\63&,6QNK:>H:"A_N!"CM0Z2@'=XRUT[`G2&N
M`\.R&PW?)<IR:BJ&;K6UB@VE0\RVO.H;?&:@D3[Z1K;Q[\7N6-8KWDRS'<\>
MV+%N?.03RWML/%N!XV/E'#F0:W6P1<B@Y:R#QNS0&>L3-%-10Y`35;=P@!2[
MZVW)N:XA<%8GCUJ?%3C=I;1Z^T3&Z:-TQW!`,_?&GXIP?-J%G,,AO%*[2Y-=
M5."GWD`E)"BF7M!E(]S#*N,.*?(7A7B9FG`^./':^BLSWE.]GO/(^_3%::66
M4@+,R",7@:LV?N2R=@LZ3-RX29J(R`LA.J9R;<X[C)&9W7BN_9Q;,FN64-JQ
MQH,AJB8"]C*D2,W%)/D22-=`9R$Y:1&>(V+EFP8'<,9M>**_<M2MWUZY\I*U
MH7,2:"QJJ1T$R-2>LC#U:;Q-Y(8A\(UFX^U'$5D>\B,H'G"6+'3!U"I3T?\`
MK;(39"4,\>.)9*)V9T2-3*H8'(AVF#;KTU'-9F>+WCZB&LIKZIC]I4SLT.%)
MVJ2VWY-):G?XC4Q)ENX[RJP_3<_B%OI7_P!V5@_N-@C<"XX-_0_*$#4`^,2-
M\/L-WWC)X[,=XV;U-X3+=1PG/RKJH,E(\95?)\ZPFK(M!%="X^G&D?U%)%;^
MX*OM=Y=^[MZZB_/;]0Y=RI4WL/C]%>N"/[A'E]`%(/EEHF0G*42Y@&,7+#N)
M*>RM,)&0,V]SR`"?KD&1]IG*<^O2&,^-OBUR0XO^/[E"6W8PFXWDKE.0R?8(
M2D#*0#BPR<A^BDH"DD&5:RJ\,BH]F5W#@G>Y*"8'$3B41U(G+^:XOF7)MK7;
M:@*Q2C2RWZLM$H2H*5I('0"4^\1EPU@F585Q9>C<:1Q.4W!;RTLR2%DJ04IZ
M3ZSG(G2*.#_$OD7QF\5/(&AJ8QDVG)W)[?+<E'T<)2OFG'$I8(-M2JJFK+)R
MXPA54V+<79>]T4"%..X@/31R#F&*97S);JPUI<P^B_+(+VW0)1);DA+4%<QT
MZ&7:$\98'EN)\(W.VN47IYE7*J'/2)`4I2QZ:"J1E/8.G33Q)C4L%P`Y353P
MK3/&NF5)S"Y_N%W<WF]8]^OPS.5G*^I=&ZCVI!,I2/T19V]JT(R/[)G0(K$*
M*)C;F$H])6<I8?7_`%#L9?<WO4Q.D0EFG<V;MJ4(\JMDNRU+UEX$])QHZ#BG
M-:7Z<G<,MC?Y;+ZE]3SS<Y%8*I%!5_F0E'3V@0W')G'+RGY9X+4#BE2N&]&P
MIC2H(U:)MT%&W>EIY&RQ.0(J/4KG((K2S:-A8LTLU3>2":SI9X[=J%[3&3`0
MUT-ES'A^P\F5>;5MZK;A7K+RZ<K0M2&PL22B>H\O0#1*1+0=8XNYX/SAD7'5
M+@5%8Z"V65M30?VJ2EQY2%34XKOYNYZGO,:1T3?^>VO_`(@'C)](0[/_`#<&
M)OI/<E[7U/\`MT->]OW._P!CO^K?B[^[L[NN^W756OW/5?\`D#]X;_\`Y7ZG
M^8]3O+?/=+_ITEX1;_\`:;7_`([_`&?Z:/\`\WT-GX=_IREX2W=XY\?\DQ"=
M_6?%%T<%QK):OE5!N)@'Y4+`,M33.B`<`V^:/&>V.V^XD+T^.K8?1LZPE-\"
MMA?*F))/4I2'!TZG4S/M`\(I[]:S+Z'+$^-_H['A,=`I12K7[!(1S&&*0X#W
M%`V^P[CU'IN7\(_#H(ATU=P.'>%D`R.@/0>[N/C%$/46/ET/\_?V/PBLP]PE
M$`[1*&Q1`1';KOT[A,`"`=.GPTWM_N%Q$TK)[:R]TYPVCR@@R*3U!`^Z49.#
MD6D+88"9?Q@3+&*G(F5>PYUS-22[..DFCYU%JNTTE3MDI%%`43*`4PE`^X%'
M35T;JZNU55J866EN,K1,R)&X2)$I:CM.-S:JJEI*^GK5I#B&74+6-1/:9RU/
M0_$^,/6YI\ML@^1//-3MZ6,AA9E.H5_&-&QA2UY6XNESL9.2D03C4BQB#^0?
M23^5_&DFA_3*F4-QV$VHCXZP*W</8M5,5E;OMZW2^M]4F@#+I+N0-#(ZGPB4
M.2<ZO'-&6TKMOH5MNMLI8:8:FLRZ;DGJ-WMF`/&.@;Q6>&C^T4I7.1_+2'9O
M<H-3(S..L1J`@_B<=.>P3M+%<##\PTE;JV[NYNU*)VT8?8PBHX`/:JUSI]0@
MR-2\2PAUQ-G62'JE.X*>'0I02?*U[Q-78RZV\X$^FYG'"UF&;,[KPB2F:=92
M4M'L7`$B:QU&LI]1'0GD"L.KG1+K3&,VYK;JV52PUIM8VK=)X\A%IR*=1I9=
MLV6.BDY<QXNO=(0QBE,8H`([:JQ15JJ*O8JRUZJ&G4KE.0.T@R/OE%MKQ1.7
M2UU=`'5,J>94V%B4T!:2"1[0#IX0U3@-PEJ?!+"#K#-9MTM?BO[E,W*6M<Y$
MQT/(23Z5:QK%)`[..47;@A',8Q)),W<)C``[Z[7D?D.Z<E9"+_<FDT[R*=#*
M4(GM2A$Y;9SZDDGKK'%\6<=V[C''UV6UOK?2]4*>4M6BMR@E,C+P"1K#VP;I
MAMMN&WV=H?O_``ZX`@D`3.T=M)'WZ?RE$B%I"M3/?XS,_C.%*B4H]!-\>GX0
M#KZAT*'325)W"1)_AT\.G2'E*W$*/S#OK_6%!(H#ON/PZ=`#I]P``:P&TA96
MG0J&O@8;VS5N42H]I]O=">PGU';J.V_X2?#U]2_'XZQZ2#-)`+2NJ9#;\)??
M"B5E.T*4/M_K.*O;+]INGW[!M]FP!MTTHHW"1.FGAI+PTC!`*PYKN'M.OOA1
M(`[^NWV?9^SIN&VEP`$+WS,X3VB[;;F^_J'7X]>FVDI0A"/32D!'A&"G=J2=
MTI3G_@0OME#;;IL&P;;>G[OCH"0D2&B/#M&5)"U;S\_CW@]LN_=UW]/].G3J
M'W:"E)D.P[02&_?^*4H3VPW$=S=0V$`$-A_AZZ4=9>PSC&U,CXD2G,SBKMZ;
M;C^_KZ;>NVL;4SW2$YS^V#;Y-DS*4O;#$/(5P=J/.S`SW&DS*)UBYU^1"U8P
MNXLOG2UFUH-E6GMR+0@@L]KLXR6,UD$2"!Q2$JA/ZB1-2+QER+6<9Y,W?Z=I
M511[=CK()&]"M)@B>J2=PF#T([S$8\M\9T7*>*+L#RTL5R%A;+Q3/8H=1U!D
MH3!(U$P=92CBMS-XP.=&#9Q]#V/CU>[7'-5U$6ENQC$/LAU>723$"(+LG-=;
MO))J"Y``W8];-E2>A@`P#KT3Q7G+CG**5+J;@Q156R:FZE7IE)ET!U"O>(\R
MLGX$Y.QJL<9>M=754H)"'*=!=2KK(R3J`?`">N@C4]>X2<R;5(I14#Q6SZ^?
M*B':DIB^U1:0%$=A.H]F(^/8(D#[3JE#[];RJY7XZI$E3U[MNT#63A/\A'.T
MW$')M5(-6.Z`GI.E?'_9I$G/';P$\M\G.H^1S;)57CY4UC)JN47KQK><@';B
M(=R32NP#HT)'N1*/J\D"B00ZICZ#"^4_55A=B;72XFW47*XK_$H%MH>]1&[X
M)^V)ZQ+Z0<XO;C=1EC]/;*$#S(20X\K_`$@[)_ZQ[HZ:N'OC<XO\*X\CG%]1
M/,Y!<-"-IC+%T%M-WQ^3LV6;L'WRZ+.M1BIA$?E8Y%LF8!V4%0>HT_SWEO-^
M17`G(*M7Z<@G8PWY&TB>DP/G($A-4YRGI.+N<=\085QK3_\`T-,%7%20%ON@
M+<)EJ1/Y`3K(=.DR(?J4G:4"[[[>HC\?M^.HSUZZ3]T2>$B4C,PHEW'??^'W
M;??K`2!,B<S"YZ2.L!2@7?;?J._72NP![",?"45:((-$$&B"#1!!H@@T00:(
M(-$$&B"#1!!H@A#>@_\`/IK!Z=_LZQD=8M!ZCZ?#_P"?[?YOOUAWY!\W4>__
M`!XQD]>_3OT^R*S?E'\WQ]=+'3M#*_E[Q;)^0?R^@^G_`#IJI^4]?N^V!G_:
MB\7\H?L#_;2D?(/<(6.D+I49@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!
'H@@T01__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
